Blockade of neurokinin-3 receptors modulates dopamine-mediated behavioral hyperactivity

Neuropharmacology

Volumn 57, Issue 3, 2009, Pages 295-301

  Nwaneshiudu, Chinwe A ^a   Unterwald, Ellen M ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

CD 1 mice; Cocaine; D1; NK 3; SB 222200; Striatum

Indexed keywords

3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; COCAINE; DOPAMINE; DOPAMINE 1 RECEPTOR; N (ALPHA ETHYLBENZYL) 3 METHYL 2 PHENYL 4 QUINOLINECARBOXAMIDE; NEUROKININ 3 RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DRUG MECHANISM; HYPERACTIVITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DENSITY; RECEPTOR UPREGULATION;

ANIMALS; BENZAZEPINES; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; MALE; MICE; MOTOR ACTIVITY; QUINOLINES; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D1; RECEPTORS, NEUROKININ-3; TIME FACTORS; TRITIUM;

EID: 67650699185     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.05.008     Document Type: Article

References (40)

1. Arenas E., Alberch J., Perez-Navarro E., Solsona C., and Marsal J. Neurokinin receptors differentially mediate endogenous acetylcholine release evoked by tachykinins in the neostriatum. J. Neurosci. 11 (1991) 2332-2338
2. Bannon M.J., Brownschidle L.A., Tian Y., Whitty C.J., Poosch M.S., D'sa C., and Moody C.A. Neurokinin-3 receptors modulate dopamine cell function and alter the effects of 6-hydroxydopamine. Brain Res. 695 (1995) 19-24
3. Bishop C., and Walker P.D. Intranigral antagonism of neurokinin 1 and 3 receptors reduces intrastriatal dopamine D1 receptor-stimulated locomotion in the rat. Brain Res. 1023 (2004) 126-133
4. Breese G.R., Duncan G.E., Napier T.C., Bondy S.C., Iorio L.C., and Mueller R.A. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. J. Pharmacol. Exp. Ther. 240 (1987) 167-176
5. Buell G., Schulz M.F., Arkinstall S.J., Maury K., Missotten M., Adami N., Talabot F., and Kawashima E. Molecular characterisation, expression and localisation of human neurokinin-3 receptor. FEBS Lett. 299 (1992) 90-95
6. Canning B.J. Neurokinin3 receptor regulation of the airways. Vascul. Pharmacol. 45 (2006) 227-234
7. Chen L.W., Guan Z.L., and Ding Y.Q. Mesencephalic dopaminergic neurons expressing neuromedin K receptor (NK3): a double immunocytochemical study in the rat. Brain Res. 780 (1998) 150-154
8. Dam T.V., Escher E., and Quirion R. Visualization of neurokinin-3 receptor sites in rat brain using the highly selective ligand [3H]senktide. Brain Res. 506 (1990) 175-179
9. de Souza Silva M.A., Mello Jr. E.L., Muller C.P., Jocham G., Maior R.S., Huston J.P., Tomaz C., and Barros M. Interaction of the tachykinin NK3 receptor agonist senktide with behavioral effects of cocaine in marmosets (Callithrix penicillata). Peptides 27 (2006) 2214-2223
10. de Souza Silva M.A., Mello Jr. E.L., Muller C.P., Jocham G., Maior R.S., Huston J.P., Tomaz C., and Barros M. The tachykinin NK3 receptor antagonist SR142801 blocks the behavioral effects of cocaine in marmoset monkeys. Eur. J. Pharmacol. 536 (2006) 269-278
11. Deschamps K., and Couture R. The ventral tegmental area as a putative target for tachykinins in cardiovascular regulation. Br. J. Pharmacol. 145 (2005) 712-727
12. Elliott P.J., Mason G.S., Stephens-Smith M., and Hagan R.M. Behavioural and biochemical responses following activation of midbrain dopamine pathways by receptor selective neurokinin agonists. Neuropeptides 19 (1991) 119-126
13. Emonds-Alt X., Bichon D., Ducoux J.P., Heaulme M., Miloux B., Poncelet M., Proietto V., Van Broeck D., Vilain P., Neliat G., et al. SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor. Life Sci. 56 (1995) PL27-32
14. Hess E.J., Albers L.J., Le H., and Creese I. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation. J. Pharmacol. Exp. Ther. 238 (1986) 846-854
15. Hess E.J., Norman A.B., and Creese I. Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on D1 and D2 dopamine receptors. J. Neurosci. 8 (1988) 2361-2370
16. Humpel C., Saria A., and Regoli D. Injection of tachykinins and selective neurokinin receptor ligands into the substantia nigra reticulata increases striatal dopamine and 5-hydroxytryptamine metabolism. Eur. J. Pharmacol. 195 (1991) 107-114
17. Jocham G., Lezoch K., Muller C.P., Kart-Teke E., Huston J.P., and de Souza Silva M.A. Neurokinin receptor antagonism attenuates cocaine's behavioural activating effects yet potentiates its dopamine-enhancing action in the nucleus accumbens core. Eur. J. Neurosci. 24 (2006) 1721-1732
18. Jocham G., Lauber A.C., Muller C.P., Huston J.P., and de Souza Silva M.A. Neurokinin 3 receptor activation potentiates the psychomotor and nucleus accumbens dopamine response to cocaine, but not its place conditioning effects. Eur. J. Neurosci. 25 (2007) 2457-2472
19. Kawaguchi Y., Wilson C.J., Augood S.J., and Emson P.C. Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci. 18 (1995) 527-535
20. Keegan K.D., Woodruff G.N., and Pinnock R.D. The selective NK3 receptor agonist senktide excites a subpopulation of dopamine-sensitive neurones in the rat substantia nigra pars compacta in vitro. Br. J. Pharmacol. 105 (1992) 3-5
21. Khawaja A.M., and Rogers D.F. Tachykinins: receptor to effector. Int. J. Biochem. Cell Biol. 28 (1996) 721-738
22. Langlois X., Wintmolders C., te Riele P., Leysen J.E., and Jurzak M. Detailed distribution of Neurokinin 3 receptors in the rat, guinea pig and gerbil brain: a comparative autoradiographic study. Neuropharmacology 40 (2001) 242-253
23. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
24. Maggi C.A. The mammalian tachykinin receptors. Gen. Pharmacol. 26 (1995) 911-944
25. Marco N., Thirion A., Mons G., Bougault I., Le Fur G., Soubrie P., and Steinberg R. Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in vivo microdialysis approach in guinea pig. Neuropeptides 32 (1998) 481-488
26. Massi M., Panocka I., and de Caro G. The psychopharmacology of tachykinin NK-3 receptors in laboratory animals. Peptides 21 (2000) 1597-1609
27. Mattingly B.A., Rowlett J.K., Ellison T., and Rase K. Cocaine-induced behavioral sensitization: effects of haloperidol and SCH 23390 treatments. Pharmacol. Biochem. Behav. 53 (1996) 481-486
28. Mileusnic D., Lee J.M., Magnuson D.J., Hejna M.J., Krause J.E., Lorens J.B., and Lorens S.A. Neurokinin-3 receptor distribution in rat and human brain: an immunohistochemical study. Neuroscience 89 (1999) 1269-1290
29. Nordquist R.E., Savignac H., Pauly-Evers M., Walker G., Knoflach F., Borroni E., Glaentzlin P., Bohrmann B., Messer J., Ozmen L., Albientz A., and Spooren W. Characterization of behavioral response to amphetamine, tyrosine hydroxylase levels, and dopamine receptor levels in neurokinin 3 receptor knockout mice. Behav. Pharmacol. 19 (2008) 518-529
30. Overton P., Elliott P.J., Hagan R.M., and Clark D. Neurokinin agonists differentially affect A9 and A10 dopamine cells in the rat. Eur. J. Pharmacol. 213 (1992) 165-166
31. Panocka I., Massi M., Lapo I., Swiderski T., Kowalczyk M., and Sadowski B. Antidepressant-type effect of the NK3 tachykinin receptor agonist aminosenktide in mouse lines differing in endogenous opioid system activity. Peptides 22 (2001) 1037-1042
32. Patacchini R., and Maggi C.A. Peripheral tachykinin receptors as targets for new drugs. Eur. J. Pharmacol. 429 (2001) 13-21
33. Preston Z., Lee K., Widdowson L., Richardson P.J., and Pinnock R.D. Tachykinins increase [3H]acetylcholine release in mouse striatum through multiple receptor subtypes. Neuroscience 95 (2000) 367-376
34. Ribeiro S.J., and De Lima T.C. Naloxone-induced changes in tachykinin NK3 receptor modulation of experimental anxiety in mice. Neurosci. Lett. 258 (1998) 155-158
35. Saka E., Iadarola M., Fitzgerald D.J., and Graybiel A.M. Local circuit neurons in the striatum regulate neural and behavioral responses to dopaminergic stimulation. Proc. Natl. Acad. Sci. U S A 99 (2002) 9004-9009
36. Sarau H.M., Griswold D.E., Bush B., Potts W., Sandhu P., Lundberg D., Foley J.J., Schmidt D.B., Webb E.F., Martin L.D., Legos J.J., Whitmore R.G., Barone F.C., Medhurst A.D., Luttmann M.A., Giardina G.A., and Hay D.W. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist. J. Pharmacol. Exp. Ther. 295 (2000) 373-381
37. Sarau H.M., Feild J.A., Ames R.S., Foley J.J., Nuthulaganti P., Schmidt D.B., Buckley P.T., Elshourbagy N.A., Brawner M.E., Luttmann M.A., Giardina G.A., and Hay D.W. Molecular and pharmacological characterization of the murine tachykinin NK(3) receptor. Eur. J. Pharmacol. 413 (2001) 143-150
38. Shigemoto R., Yokota Y., Tsuchida K., and Nakanishi S. Cloning and expression of a rat neuromedin K receptor cDNA. J. Biol. Chem. 265 (1990) 623-628
39. Spooren W., Riemer C., and Meltzer H. Opinion: NK3 receptor antagonists: the next generation of antipsychotics?. Nat. Rev. Drug Discov. 4 (2005) 967-975
40. Stoessl A.J., Szczutkowski E., Glenn B., and Watson I. Behavioural effects of selective tachykinin agonists in midbrain dopamine regions. Brain Res. 565 (1991) 254-262